Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics.
Nozima AripovaJoel M KremerDimitrios A PappasGeorge ReedBryant R EnglandBill H RobinsonJeffrey R CurtisGeoffrey M ThieleTed R MikulsPublished in: Rheumatology (Oxford, England) (2023)
An expanded ACPA profile appears to be more strongly associated with biologic treatment response in RA than commercially available anti-CCP3 antibody levels. However, further enhancements to PCA will be needed to effectively prioritize between different biologics available for the treatment of RA.